Corient Private Wealth
LUCD icon

Corient Private Wealth’s Lucid Diagnostics LUCD Stock Holding History

Corient Private Wealth’s Portfolio LUCD Stock Details LUCD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.7K Buy
+10,028
New +$10.8K ﹤0.01% 3034

Other funds holding LUCD

Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
MCM
Masters Capital Management Atlanta, Georgia $3.9B AUM 50.88% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
First Manhattan
First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Corient Private Wealth's LUCD Position: Q2 2026 in Review

Corient Private Wealth opened a new position in Lucid Diagnostics (LUCD) in Q2 2026: 10,028 shares worth $10.7K. The stake represents ﹤0.01% of the portfolio and ranks #3034 among its holdings.

116 funds tracked by Wall St. Rank hold LUCD as of Q2 2026.

  • Corient Private Wealth held 10,028 shares of Lucid Diagnostics worth $10.7K as of Q2 2026.
  • Lucid Diagnostics was a new Corient Private Wealth position in Q2 2026.
  • Lucid Diagnostics made up ﹤0.01% of Corient Private Wealth's portfolio in Q2 2026, its #3034 holding.
  • 116 funds tracked by Wall St. Rank held Lucid Diagnostics as of Q2 2026.

Based on Corient Private Wealth's 13F filing for Q2 2026, filed 12 Aug 2026.